AGEN1884
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for AGEN1884, covering 2024-04-04 to 2025-03-17. Get the full timeline:
Most recent: Clinical Trial Update: AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy [Phase 1, Phase 2]